Terumo Corp (TRUMF)
19.98
+0.04
(+0.18%)
USD |
OTCM |
Dec 16, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 29.66B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 21.22% |
| Valuation | |
| PE Ratio | 37.70 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.636 |
| Price to Book Value | 3.225 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0863 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1747 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 55.98% |
Profile
| Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue. |
| URL | https://www.terumo.com |
| Investor Relations URL | https://www.terumo.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |
Ratings
Profile
| Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue. |
| URL | https://www.terumo.com |
| Investor Relations URL | https://www.terumo.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |